甲状腺未分化癌的综合治疗

殷德涛; 张朋宇

doi:10.3971/j.issn.1000-8578.2022.21.1276

甲状腺未分化癌的综合治疗

450052 郑州，郑州大学第一附属医院甲状腺外科

基金项目:

河南省中医药研究重大专项 20-21ZYZD14

河南省中青年科技创新领军人才项目 YXKC2020015

详细信息

作者简介:
殷德涛主任医师、二级教授、博士生导师、郑州大学第一附属医院河医院区甲状腺外科主任。中国医师协会外科学分会甲状腺外科医师委员会（CTA）委员；中国研医会甲状腺委员会常委，青委会副主委；中国中西医结合学会理事；河南省中西医结合学会甲状腺分会主任委员等。《Thyroid》《Anti-cancer Agents》《Archives of Medical Research》特约审稿人；担任《中国普通外科杂志》《中华医学杂志》《中华实验外科杂志》《中华内分泌外科杂志》《国际外科学杂志》等编委或通信编委。作为第一完成人，获河南省科技进步奖二等奖两项，主持国家自然科学基金面上项目一项，省部级科研课题25项，在国家级核心期刊发表学术论著一百余篇，SCl收录期刊发表学术论著二十余篇。荣获河南省高层次人才特殊支持“中原千人计划”学者、河南省优秀专家、河南省学术技术带头人、河南省青年科技专家、河南省高校省级青年骨干教师等荣誉二十余项。

中图分类号: R736.1
计量
- 文章访问数: 2670
- HTML全文浏览量: 575
- PDF下载量: 490
出版历程
- 收稿日期: 2021-11-04
- 修回日期: 2021-12-09
- 网络出版日期: 2024-01-12
- 刊出日期: 2022-02-24

Comprehensive Treatment of Anaplastic Thyroid Cancer

Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

Funding:

Major Scientific Research Projects of Traditional Chinese Medicine in Henan Province 20-21ZYZD14

Cultivation of Young and Middle-aged Health Science and Technology Innovation Leading Talents in Henan Province YXKC2020015

摘要

摘要:
甲状腺未分化癌（ATC）是一种罕见的肿瘤，占甲状腺癌的1%~2%，其死亡病例占甲状腺癌致死病例的大多数。目前，主要采用的治疗方式包括手术、放疗、化疗、靶向治疗和免疫治疗。本文根据最新的美国甲状腺学会（ATA）指南和近年相关文献，阐述ATC的综合治疗方式以提高ATC患者的生存率和生活质量。
- 甲状腺未分化癌（ATC） /
- 手术治疗 /
- 放化疗 /
- 免疫治疗 /
- 靶向治疗
Abstract:
Anaplastic thyroid cancer (ATC) is a rare malignancy, accounting for 1%-2% of all thyroid cancers, however, ATC accounts for the majority of deaths from thyroid cancer. Currently, the main comprehensive treatments are surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. Based on the latest American Thyroid Association guidelines and the related literatures, we summarize the most reasonable and effective therapeutic strategies to improve the survival rate of patients with ATC as well as the quality of life.
- Anaplastic thyroid cancer /
- Surgery /
- Chemoradiotherapy /
- Immunotherapy /
- Targeted therapy
Competing interests: The authors declare that they have no competing interests.

作者贡献：

殷德涛：论文设计与撰写

张朋宇：文献搜集、整理与论文撰写

HTML全文

Competing interests: The authors declare that they have no competing interests.

作者贡献：

殷德涛：论文设计与撰写

张朋宇：文献搜集、整理与论文撰写

参考文献(28)

[1]	王龙龙, 李红强, 苌群刚, 等. 甲状腺癌21980例患者临床病理特征与发病趋势分析[J]. 中华医学杂志, 2020, 100(14): 1072-1076. doi: 10.3760/cma.j.cn112137-20190905-01972 Wang LL, Li HQ, Chang QG, et al. Clinical pathology and incidence trend of thyroid cancer based on 21 980 cases[J]. Zhonghua Yi Xue Za Zhi, 2020, 100(14): 1072-1076. doi: 10.3760/cma.j.cn112137-20190905-01972
[2]	Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis[J]. Am J Transl Res, 2019, 11(9): 5888-5896.
[3]	Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019[J]. JAMA Oncol, 2020, 6(9): 1397-1404. doi: 10.1001/jamaoncol.2020.3362
[4]	刘敬敬, 曹水. 甲状腺未分化癌88例治疗及预后分析[J]. 肿瘤防治研究, 2019, 46(5): 431-435. doi: 10.3971/j.issn.1000-8578.2019.18.1639 Liu JJ, Cao S. Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 88 Cases[J]. Zhong Liu Fang Zhi Yan Jiu, 2019, 46(5): 431-435. doi: 10.3971/j.issn.1000-8578.2019.18.1639
[5]	Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer[J]. Thyroid, 2021, 31(3): 337-386. doi: 10.1089/thy.2020.0944
[6]	Hu S, Helman SN, Hanly E, et al. The role of surgery in anaplastic thyroid cancer: A systematic review[J]. Am J Otolaryngol, 2017, 38(3): 337-350. doi: 10.1016/j.amjoto.2017.02.005
[7]	Ahmed S, Ghazarian MP, Cabanillas ME, et al. Imaging of Anaplastic Thyroid Carcinoma[J]. AJNR Am J Neuroradiol, 2018, 39(3): 547-551. doi: 10.3174/ajnr.A5487
[8]	Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective[J]. Mol Cancer, 2018, 17(1): 154. doi: 10.1186/s12943-018-0903-0
[9]	Wang JR, Zafereo ME, Dadu R, et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma[J]. Thyroid, 2019, 29(8): 1036-1043. doi: 10.1089/thy.2019.0133
[10]	Tashima L, Mitzner R, Durvesh S, et al. Dyspnea as a prognostic factor in anaplastic thyroid carcinoma[J]. Eur Arch Otorhinolaryngol, 2012, 269(4): 1251-1255. doi: 10.1007/s00405-011-1762-0
[11]	殷德涛, 刘晨光. 甲状腺癌的放射治疗[J]. 中国实用外科杂志, 2019, 39(3): 206-208. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201903004.htm Yin DT, Liu CG. Radiotherapy for thyroid cancer[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2019, 39(3): 206-208. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201903004.htm
[12]	Glaser SM, Mandish SF, Gill BS, et al. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival[J]. Head Neck, 2016, 38 Suppl 1: E2083-E2090.
[13]	Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base[J]. Cancer, 2017, 123(9): 1653-1661. doi: 10.1002/cncr.30493
[14]	Takahashi N, Matsushita H, Umezawa R, et al. Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution[J]. Eur Thyroid J, 2019, 8(1): 24-30. doi: 10.1159/000493315
[15]	Zhou W, Yue Y, Zhang X. Radiotherapy Plus Chemotherapy Leads to Prolonged Survival in Patients With Anaplastic Thyroid Cancer Compared With Radiotherapy Alone Regardless of Surgical Resection and Distant Metastasis: A Retrospective Population Study[J]. Front Endocrinol (Lausanne), 2021, 12: 748023. doi: 10.3389/fendo.2021.748023
[16]	Xia Q, Wang W, Xu J, et al. Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma[J]. Onco Targets Ther, 2018, 11: 2251-2257. doi: 10.2147/OTT.S153759
[17]	Abe I, Lam AK. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics[J]. Curr Oncol Rep, 2021, 23(3): 31. doi: 10.1007/s11912-021-01019-9
[18]	Prasongsook N, Kumar A, Chintakuntlawar AV, et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer[J]. J Clin Endocrinol Metab, 2017, 102(12): 4506-4514. doi: 10.1210/jc.2017-01180
[19]	Pozdeyev N, Gay LM, Sokol ES, et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers[J]. Clin Cancer Res, 2018, 24(13): 3059-3068. doi: 10.1158/1078-0432.CCR-18-0373
[20]	Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer[J]. J Clin Oncol, 2018, 36(1): 7-13. doi: 10.1200/JCO.2017.73.6785
[21]	Savvides P, Nagaiah G, Lavertu P, et al. Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid, 2013, 23(5): 600-604. doi: 10.1089/thy.2012.0103
[22]	Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors[J]. Cancer Treat Rev, 2016, 42: 47-55. doi: 10.1016/j.ctrv.2015.11.003
[23]	Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to Everolimus in anaplastic thyroid Cancer[J]. N Engl J Med, 2014, 371(15): 1426-1433. doi: 10.1056/NEJMoa1403352
[24]	Xu B, Fuchs T, Dogan S, et al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases[J]. Thyroid, 2020, 30(10): 1505-1517. doi: 10.1089/thy.2020.0086
[25]	French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers[J]. Lancet Diabetes Endocrinol, 2017, 5(6): 469-481. doi: 10.1016/S2213-8587(16)30277-7
[26]	Zwaenepoel K, Jacobs J, De Meulenaere A, et al. CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy[J]. Histopathology, 2017, 71(3): 357-365. doi: 10.1111/his.13230
[27]	Naing A, Gainor JF, Gelderblom H, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors[J]. J Immunother Cancer, 2020, 8(1): e000530. doi: 10.1136/jitc-2020-000530
[28]	Capdevila J, Wirth LJ, Ernst T, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma[J]. J Clin Oncol, 2020, 38(23): 2620-2627. doi: 10.1200/JCO.19.02727